EcoDrugPlus

Hypocretin Receptor 2

Ensembl ID : ENSOMEG00000000962
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSOMEG00000018133
Gene Symbol: LOC112136551
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSOMEG00000017438
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSOMEG00000007704
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1a

Ensembl ID : ENSOMEG00000007892
Gene Symbol: LOC112152856
4 Cross references
258 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSOMEG00000002876
Gene Symbol: INPP5D
3 Cross references
215 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSOMEG00000012348
Gene Symbol: INSR
3 Cross references
213 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSOMEG00000000314
Gene Symbol: LOC112150803
3 Cross references
212 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSOMEG00000006084
Gene Symbol: LOC112152311
3 Cross references
204 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSOMEG00000018503
Gene Symbol: IGF1RB
1 Cross references
203 Possible Orthologues:

Integrin Alpha-5-Like

Ensembl ID : ENSOMEG00000021016
Gene Symbol: LOC112158870
3 Cross references
206 Possible Orthologues:

Integrin Beta-1-Like

Ensembl ID : ENSOMEG00000002896
Gene Symbol: LOC112150849
3 Cross references
228 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).